The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing
Jul 19, 2024•almost 2 years ago
Contract Type
agreement
ManassasBiotechnology
Description
Capra Biosciences has been awarded a new $7.5 million, two-year project agreement through the BioMaP-Consortium to demonstrate the ability of its platform to rapidly scale and manufacture biologically derived small molecule active pharmaceutical ingredients (APIs). The agreement includes the demonstration of the manufacture of three active pharmaceutical ingredients, selected in cooperation with the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
Company Information
Company
Capra Biosciences
Location
11100 ENDEAVOR CT UNIT 149
Manassas, Virginia, United States
About
Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.
ManassasBiotechnology